Valganciclovir

ApprovedWithdrawn

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Giant Lymph Node Hyperplasia

Conditions

Giant Lymph Node Hyperplasia

Trial Timeline

Dec 1, 2008 → May 1, 2009

NCT ID

NCT00361933

About Valganciclovir

Valganciclovir is a approved stage product being developed by Roche for Giant Lymph Node Hyperplasia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00361933. Target conditions include Giant Lymph Node Hyperplasia.

What happened to similar drugs?

4 of 13 similar drugs in Giant Lymph Node Hyperplasia were approved

Approved (4) Terminated (2) Active (7)

✅PexidartinibDaiichi SankyoApproved

✅Tocilizumab + PrednisoneRocheApproved

✅DenosumabAmgenApproved

✅XGEVA®AmgenApproved

🔄PexidartinibDaiichi SankyoPhase 3

🔄Upadacitinib + Corticosteroid (CS)AbbViePhase 3

🔄Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002222	Pre-clinical	Completed	—	—	Cytomegalovirus Retinitis
NCT00017784	Phase 3	UNKNOWN	—	—	Cytomegalovirus Retinitis
NCT01663740	Approved	Completed	Jan 30, 2012	Dec 30, 2016	Cytomegalovirus Infections
NCT00361933	Approved	Withdrawn	Dec 1, 2008	May 1, 2009	Giant Lymph Node Hyperplasia
NCT00275314	Phase 3	Terminated	Feb 1, 2006	Apr 1, 2006	Kidney Transplant
NCT00227370	Phase 3	Completed	Jul 1, 2003	Dec 1, 2008	Cytomegalovirus Infections
NCT00374686	Pre-clinical	Completed	Mar 1, 2003	Sep 1, 2005	Cytomegalovirus Infection
NCT00275665	Phase 3	Completed	Nov 1, 2001	Jul 1, 2007	Bone Marrow Stem Cell Transplant

Competing Products

20 competing products in Giant Lymph Node Hyperplasia

See all competitors

Product	Company	Stage	Hype Score
prednisone	Kiniksa Pharmaceuticals	Phase 2	29
Pexidartinib	Daiichi Sankyo	Phase 2	39
Pexidartinib	Daiichi Sankyo	Phase 3	44
Pexidartinib	Daiichi Sankyo	Approved	43
Baricitinib	Eli Lilly	Phase 2	35
Upadacitinib + Corticosteroid (CS)	AbbVie	Phase 3	40
dovitinib	Novartis	Phase 2	35
Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.	Novartis	Phase 3	40
Secukinumab 300 mg, s.c. + Prednisolone + Placebo	Novartis	Phase 2	35
Secukinumab	Novartis	Phase 1	29
Secukinumab 300 mg + Secukinumab 150 mg	Novartis	Phase 3	40
Tocilizumab + Placebo	Roche	Phase 3	44
Tocilizumab + Prednisone	Roche	Approved	43
Tocilizumab	Roche	Phase 3	40
Tocilizumab	Roche	Phase 1	29
Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate	Roche	Phase 3	40
Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs)	Roche	Phase 2	35
tocilizumab and IV steroids combination	Roche	Phase 2	31
Denosumab	Amgen	Approved	43
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]	Amgen	Phase 2	27